CytoDyn – Company files an IND and a Phase 2 Protocol for Treatment of NASH
CytoDyn Inc (OTCQB: CYDY), a clinical stage biotechnology company, announced the filing of an Investigational Drug License (IND) for treatment of NASH with Leronlimab. The drug candidate is a humanized IgG4 mAb CCR5 antagonist that has been granted the Fast Track designation by the FDA...
